New cancer drug BAY2965501 enters first human tests
NCT ID NCT05614102
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called BAY2965501, which boosts the immune system to fight cancer. It is given alone or with other drugs like pembrolizumab and chemotherapy. The study includes about 284 people with advanced solid tumors (skin, kidney, stomach, or lung cancer) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the drug affects tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BAY2965501 (a drug that activates T-cells to fight cancer)
What this could lead to
If it works, this could point toward a new immunotherapy option for advanced solid tumors that are hard to treat.
What could go wrong
This is a very early Phase 1 trial, so the drug may not be effective or could cause serious side effects. It is also only tested in a small number of people.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Antwerp University Hospital | Oncology Department
Antwerp, 2650, Belgium
-
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
Shenzhen, 518172, China
-
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, 100000, China
-
Clinica Universidad De Navarra | Madrid | Oncologia
Madrid, 28027, Spain
-
Clinica Universidad De Navarra | Pamplona | Oncologia
Pamplona, Madrid, 31008, Spain
-
Freeman Hospital
Newcastle upon Tyne, Tyne and Wear, NE7 7DN, United Kingdom
-
Ghent University Hospital | Drug Research Unit Department
Ghent, 9000, Belgium
-
Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital
London, Greater London, SE1 9RT, United Kingdom
-
Hospital Hm Nou Delfos | Oncologia
Barcelona, 08023, Spain
-
Hospital Universitari Vall D Hebron | Oncologia
Barcelona, 08035, Spain
-
Hospital Universitario Hm Sanchinarro | Oncologia
Madrid, 28050, Spain
-
National Cancer Center Hospital East
Kashiwa, Chiba, 277-8577, Japan
-
Oxford University Hospitals NHS Foundation Trust | Churchill Hospital - Oncology
Oxford, Oxfordshire, OX3 7LE, United Kingdom
-
Royal Marsden NHS Trust (Surrey)
Sutton, Surrey, SM2 5PT, United Kingdom
-
START | San Antonio
San Antonio, Texas, 78229, United States
-
Samsung Medical Center - Oncology Department
Seoul, 135-710, South Korea
-
Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's
Denver, Colorado, 80218, United States
-
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggido, 13620, South Korea
-
Severance Hospital, Yonsei University Health System - Oncology Department
Seoul, Seoul Teugbyeolsi, 03722, South Korea
-
Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine - Oncology Department
Hangzhou, Zhejiang, 310016, China
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States